Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Thyrocare Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: THYROCARE has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: THYROCARE underperformed the Indian Healthcare industry which returned 32.1% over the past year.
Return vs Market: THYROCARE exceeded the Indian Market which returned 10.7% over the past year.
Price Volatility Vs. Market
How volatile is Thyrocare Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StDoes Thyrocare Technologies Limited's (NSE:THYROCARE) Past Performance Indicate A Stronger Future?
2 weeks ago | Simply Wall StHere's What Thyrocare Technologies Limited's (NSE:THYROCARE) P/E Is Telling Us
1 month ago | Simply Wall StThyrocare Technologies Limited (NSE:THYROCARE) Insiders Increased Their Holdings
Is Thyrocare Technologies undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: THYROCARE (₹615.6) is trading above our estimate of fair value (₹326.03)
Significantly Below Fair Value: THYROCARE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: THYROCARE is poor value based on its PE Ratio (30.8x) compared to the Healthcare industry average (22.3x).
PE vs Market: THYROCARE is poor value based on its PE Ratio (30.8x) compared to the Indian market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: THYROCARE is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: THYROCARE is overvalued based on its PB Ratio (8.7x) compared to the IN Healthcare industry average (2.2x).
How is Thyrocare Technologies forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: THYROCARE's forecast earnings growth (12.8% per year) is above the savings rate (6.5%).
Earnings vs Market: THYROCARE's earnings (12.8% per year) are forecast to grow slower than the Indian market (20.6% per year).
High Growth Earnings: THYROCARE's earnings are forecast to grow, but not significantly.
Revenue vs Market: THYROCARE's revenue (12.4% per year) is forecast to grow faster than the Indian market (9% per year).
High Growth Revenue: THYROCARE's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: THYROCARE's Return on Equity is forecast to be high in 3 years time (27.4%)
How has Thyrocare Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: THYROCARE has a high level of non-cash earnings.
Growing Profit Margin: THYROCARE's current net profit margins (24.3%) are higher than last year (23.8%).
Past Earnings Growth Analysis
Earnings Trend: THYROCARE's earnings have grown by 16.6% per year over the past 5 years.
Accelerating Growth: THYROCARE's earnings growth over the past year (13.2%) is below its 5-year average (16.6% per year).
Earnings vs Industry: THYROCARE earnings growth over the past year (13.2%) underperformed the Healthcare industry 26.2%.
Return on Equity
High ROE: THYROCARE's Return on Equity (28.6%) is considered high.
Return on Assets
Return on Capital Employed
How is Thyrocare Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: THYROCARE's short term assets (₹1.2B) exceed its short term liabilities (₹570.1M).
Long Term Liabilities: THYROCARE's short term assets (₹1.2B) exceed its long term liabilities (₹209.1M).
Debt to Equity History and Analysis
Debt Level: THYROCARE's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: THYROCARE's debt to equity ratio has reduced from 2.1% to 0.7% over the past 5 years.
Debt Coverage: THYROCARE's debt is well covered by operating cash flow (5503.4%).
Interest Coverage: THYROCARE's interest payments on its debt are well covered by EBIT (137.1x coverage).
Inventory Level: THYROCARE has a high level of physical assets or inventory.
Debt Coverage by Assets: THYROCARE's debt is covered by short term assets (assets are 46.1x debt).
What is Thyrocare Technologies's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: THYROCARE's dividend (1.62%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: THYROCARE's dividend (1.62%) is low compared to the top 25% of dividend payers in the Indian market (2.58%).
Stability and Growth of Payments
Stable Dividend: THYROCARE has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: THYROCARE's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (99.5%), THYROCARE's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: THYROCARE's dividends in 3 years are forecast to be well covered by earnings (47.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Velumani Arokiaswamy (60yo)
Dr. Velumani Arokiaswamy, Ph.D., is the Founder of Nueclear Healthcare Ltd. in 2011 and serves as its Chief Executive Officer and also has been Managing Director since April 1, 2014 and has been its Direct ...
CEO Compensation Analysis
Compensation vs Market: Velumani's total compensation ($USD0.17) is below average for companies of similar size in the Indian market ($USD381.16K).
Compensation vs Earnings: Velumani's compensation has been consistent with company performance over the past year.
|CFO & Executive Director||20.1yrs||₹6.00m||5.05% ₹1.6b|
|Non-Executive Director||4yrs||₹16.00m||1.42% ₹465.2m|
|Independent Director||5.5yrs||₹170.00k||no data|
|Independent Director||5.5yrs||₹140.00k||no data|
|Independent Director||5.4yrs||₹60.00k||no data|
|Non-Executive Independent Director||2.5yrs||₹10.00k||no data|
Experienced Board: THYROCARE's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Thyrocare Technologies Limited's company bio, employee growth, exchange listings and data sources
- Name: Thyrocare Technologies Limited
- Ticker: THYROCARE
- Exchange: NSEI
- Founded: 1996
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: ₹32.663b
- Shares outstanding: 52.84m
- Website: https://www.thyrocare.com
Number of Employees
- Thyrocare Technologies Limited
- D/37-3, TTC Industrial Area
- MIDC Turbhe
- Navi Mumbai
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|539871||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||May 2016|
|THYROCARE||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||May 2016|
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. The company operates through Diagnostic Testing Services, Imaging Services, and Others segments. It conducts medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include 51 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also provides PET-CT scan imaging diagnostic services. Thyrocare Technologies Limited was founded in 1996 and is headquartered in Navi Mumbai, India.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 13:13|
|End of Day Share Price||2020/02/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.